NASDAQ:NERV - Minerva Neurosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.00 +0.30 (+3.90 %)
(As of 05/23/2018 01:21 AM ET)
Previous Close$8.00
Today's Range$7.50 - $8.25
52-Week Range$4.80 - $11.15
Volume206,382 shs
Average Volume181,032 shs
Market Capitalization$308.06 million
P/E Ratio-7.41
Dividend YieldN/A
Beta1.43

About Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences logoMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company' preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

Receive NERV News and Ratings via Email

Sign-up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NERV
CUSIPN/A
Phone617-600-7373

Debt

Debt-to-Equity RatioN/A
Current Ratio15.85
Quick Ratio15.85

Price-To-Earnings

Trailing P/E Ratio-7.41
Forward P/E Ratio-5.48
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.40 per share
Price / Book2.35

Profitability

EPS (Most Recent Fiscal Year)($1.08)
Net Income$-31,520,000.00
Net MarginsN/A
Return on Equity-35.48%
Return on Assets-25.14%

Miscellaneous

Employees12
Outstanding Shares38,750,000

Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences (NASDAQ:NERV) released its quarterly earnings data on Thursday, May, 3rd. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.04. View Minerva Neurosciences' Earnings History.

What price target have analysts set for NERV?

2 analysts have issued 12-month price targets for Minerva Neurosciences' shares. Their forecasts range from $11.00 to $20.00. On average, they expect Minerva Neurosciences' stock price to reach $15.50 in the next twelve months. View Analyst Ratings for Minerva Neurosciences.

Who are some of Minerva Neurosciences' key competitors?

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the folowing people:
  • Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 57)
  • Mr. Geoffrey Robin Race FCMA, MBA, Exec. VP, CFO & Chief Bus. Officer (Age 57)
  • Mr. Joseph Reilly, Sr. VP & COO (Age 43)
  • Mr. Richard Russell, Pres
  • Mr. Frederick W. Ahlholm CPA, Sr. VP & Chief Accounting Officer (Age 52)

Has Minerva Neurosciences been receiving favorable news coverage?

News headlines about NERV stock have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Minerva Neurosciences earned a news impact score of 0.18 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.53 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Minerva Neurosciences' major shareholders?

Minerva Neurosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Highland Capital Management LP (5.80%), BlackRock Inc. (5.06%), Millennium Management LLC (2.31%), JPMorgan Chase & Co. (1.55%), Northern Trust Corp (0.78%) and Artal Group S.A. (0.77%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Marc D Beer, Mark S Levine, Remy Luthringer and Venture Associates L Index III. View Institutional Ownership Trends for Minerva Neurosciences.

Which institutional investors are selling Minerva Neurosciences stock?

NERV stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BlackRock Inc. and Northern Trust Corp. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly and Remy Luthringer. View Insider Buying and Selling for Minerva Neurosciences.

Which institutional investors are buying Minerva Neurosciences stock?

NERV stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, Highland Capital Management LP, Artal Group S.A. and Alps Advisors Inc.. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer and Marc D Beer. View Insider Buying and Selling for Minerva Neurosciences.

How do I buy shares of Minerva Neurosciences?

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $8.00.

How big of a company is Minerva Neurosciences?

Minerva Neurosciences has a market capitalization of $308.06 million. The biopharmaceutical company earns $-31,520,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis. Minerva Neurosciences employs 12 workers across the globe.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]


MarketBeat Community Rating for Minerva Neurosciences (NERV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  148 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  284
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe NERV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NERV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Minerva Neurosciences (NASDAQ:NERV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Minerva Neurosciences in the last 12 months. Their average twelve-month price target is $15.50, suggesting that the stock has a possible upside of 93.75%. The high price target for NERV is $20.00 and the low price target for NERV is $11.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.50$15.50$16.00$16.00
Price Target Upside: 93.75% upside156.20% upside164.46% upside164.46% upside

Minerva Neurosciences (NASDAQ:NERV) Consensus Price Target History

Price Target History for Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences (NASDAQ:NERV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/1/2017CitigroupInitiated CoverageBuy$11.00HighView Rating Details
6/1/2017JMP SecuritiesReiterated RatingOutperform$17.00 ➝ $20.00LowView Rating Details
3/6/2017Jefferies GroupInitiated CoverageBuy ➝ Buy$17.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Minerva Neurosciences (NASDAQ:NERV) Earnings History and Estimates Chart

Earnings by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences (NASDAQ:NERV) Earnings Estimates

2018 EPS Consensus Estimate: ($1.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.30)($0.30)($0.30)
Q2 20181($0.35)($0.35)($0.35)
Q3 20181($0.39)($0.39)($0.39)
Q4 20181($0.41)($0.41)($0.41)

Minerva Neurosciences (NASDAQ NERV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018Q1 2018($0.28)($0.32)ViewListenView Earnings Details
3/12/2018Q4 2017($0.43)($0.24)ViewN/AView Earnings Details
11/6/2017Q3 2017($0.0030)($0.28)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.3350)($0.27)ViewListenView Earnings Details
5/4/2017Q1 2017($0.2950)($0.30)ViewListenView Earnings Details
3/13/2017Q4 2016($0.25)($0.27)ViewN/AView Earnings Details
11/3/2016Q316($0.21)($0.24)ViewListenView Earnings Details
8/4/2016Q116($0.30)($0.18)ViewListenView Earnings Details
5/3/2016Q1($0.33)($0.29)ViewListenView Earnings Details
3/14/2016Q4($0.31)($0.34)ViewListenView Earnings Details
11/5/2015Q315($0.43)($0.24)ViewListenView Earnings Details
8/5/2015Q215($0.53)($0.27)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.64)($0.31)ViewN/AView Earnings Details
3/26/2015Q414($0.53)($0.40)ViewN/AView Earnings Details
11/6/2014Q3 2014($2.30)($1.53)ViewN/AView Earnings Details
8/7/2014Q2($0.41)($2.33)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Minerva Neurosciences (NASDAQ:NERV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Minerva Neurosciences (NASDAQ NERV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 70.59%
Insider Trading History for Minerva Neurosciences (NASDAQ:NERV)
Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences (NASDAQ NERV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2017Frederick W AhlholmSVPSell1,661$5.80$9,633.8010,000View SEC Filing  
12/14/2017Geoff RaceCFOSell5,829$5.79$33,749.91197,698View SEC Filing  
12/14/2017Joseph H ReillyCOOSell2,906$5.80$16,854.8017,083View SEC Filing  
12/14/2017Remy LuthringerCEOSell2,194$5.85$12,834.9018,750View SEC Filing  
3/20/2017Marc D BeerDirectorBuy50,000$8.12$406,000.0025,000View SEC Filing  
2/6/2017Geoff RaceCFOSell21,450$11.02$236,379.00186,890View SEC Filing  
2/6/2017Remy LuthringerCEOSell34,281$11.02$377,776.6232,096View SEC Filing  
1/11/2017Joseph H ReillyCOOSell1,600$12.03$19,248.009,933View SEC Filing  
1/4/2017Mark S LevineSVPSell17,500$12.00$210,000.0017,250View SEC Filing  
12/27/2016Frederick W AhlholmSVPSell17,000$12.51$212,670.0022,000View SEC Filing  
8/10/2016Venture Associates L Index IIIMajor ShareholderSell1,000,000$10.00$10,000,000.00View SEC Filing  
6/21/2016David KupferDirectorBuy55,635$10.84$603,083.40209,188View SEC Filing  
3/17/2016David KupferDirectorBuy181,488$5.51$999,998.88181,488View SEC Filing  
3/18/2015Care Capital Iii LlcMajor ShareholderSell1,206,700$5.75$6,938,525.00View SEC Filing  
3/18/2015Rubertis Francesco DeDirectorBuy202,634$4.81$974,669.54View SEC Filing  
3/13/2015& Johnson JohnsonMajor ShareholderBuy607,903$4.81$2,924,013.43View SEC Filing  
1/26/2015Care Capital Iii LlcMajor ShareholderSell482,112$5.11$2,463,592.32View SEC Filing  
1/8/2015Care Capital Iii LlcMajor ShareholderSell531,808$7.38$3,924,743.04View SEC Filing  
7/7/2014Care Capital Iii LlcMajor ShareholderBuy737,500$6.00$4,425,000.00View SEC Filing  
7/7/2014Michele OllierDirectorBuy1,620,833$6.00$9,724,998.00View SEC Filing  
7/1/2014Coelho Rogerio VivaldiCEOBuy41,667$6.00$250,002.00View SEC Filing  
7/1/2014Frederick W AhlholmCAOBuy10,000$6.00$60,000.00View SEC Filing  
7/1/2014Geoff RaceCFOBuy33,333$6.00$199,998.00View SEC Filing  
7/1/2014Heek G Jan VanDirectorBuy3,333$6.00$19,998.00View SEC Filing  
7/1/2014Joseph H ReillyInsiderBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Minerva Neurosciences (NASDAQ NERV) News Headlines

Source:
DateHeadline
Zacks: Brokerages Anticipate Minerva Neurosciences (NERV) Will Announce Earnings of -$0.35 Per ShareZacks: Brokerages Anticipate Minerva Neurosciences (NERV) Will Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - May 18 at 3:19 PM
ValuEngine Upgrades Minerva Neurosciences (NERV) to SellValuEngine Upgrades Minerva Neurosciences (NERV) to Sell
www.americanbankingnews.com - May 17 at 10:23 PM
Minerva Neurosciences roluperidone shows treatment effect in schizophrenia patients; shares ahead 13% premarketMinerva Neurosciences' roluperidone shows treatment effect in schizophrenia patients; shares ahead 13% premarket
seekingalpha.com - May 17 at 6:38 PM
Minerva Neurosciences shares rise 5% on trial results for schizophrenia drugMinerva Neurosciences shares rise 5% on trial results for schizophrenia drug
finance.yahoo.com - May 17 at 6:38 PM
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp...Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp...
finance.yahoo.com - May 17 at 8:22 AM
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in SchizophreniaJournal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia
finance.yahoo.com - May 17 at 8:22 AM
Minerva Neurosciences (NERV) Rating Lowered to Hold at Zacks Investment ResearchMinerva Neurosciences (NERV) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 15 at 11:50 AM
Minerva Neurosciences (NERV) Posts Quarterly  Earnings Results, Misses Estimates By $0.04 EPSMinerva Neurosciences (NERV) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - May 4 at 8:15 PM
Edited Transcript of NERV earnings conference call or presentation 3-May-18 12:30pm GMTEdited Transcript of NERV earnings conference call or presentation 3-May-18 12:30pm GMT
finance.yahoo.com - May 4 at 8:18 AM
Minerva Neurosciences (NERV) CEO Dr. Remy Luthringer on Q1 2018 Results - Earnings Call TranscriptMinerva Neurosciences' (NERV) CEO Dr. Remy Luthringer on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 5:24 PM
Minerva Neurosciences: 1Q Earnings SnapshotMinerva Neurosciences: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 5:24 PM
Minerva Neurosciences (NERV) Raised to Sell at ValuEngineMinerva Neurosciences (NERV) Raised to Sell at ValuEngine
www.americanbankingnews.com - May 3 at 11:50 AM
BRIEF-Minerva Neurosciences Reports Q1 Loss Per Share $0.32BRIEF-Minerva Neurosciences Reports Q1 Loss Per Share $0.32
www.reuters.com - May 3 at 8:17 AM
Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business UpdatesMinerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
finance.yahoo.com - May 3 at 8:17 AM
-$0.30 Earnings Per Share Expected for Minerva Neurosciences (NERV) This Quarter-$0.30 Earnings Per Share Expected for Minerva Neurosciences (NERV) This Quarter
www.americanbankingnews.com - May 1 at 1:06 AM
Minerva Neurosciences (NERV) Downgraded by ValuEngineMinerva Neurosciences (NERV) Downgraded by ValuEngine
www.americanbankingnews.com - April 27 at 10:20 PM
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018
finance.yahoo.com - April 26 at 5:16 PM
Minerva Neurosciences (NERV) Lowered to Sell at BidaskClubMinerva Neurosciences (NERV) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 16 at 8:06 PM
Minerva Neurosciences (NERV) Expected to Announce Earnings of -$0.30 Per ShareMinerva Neurosciences (NERV) Expected to Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - April 14 at 3:17 AM
Zacks Investment Research Upgrades Minerva Neurosciences (NERV) to "Buy"Zacks Investment Research Upgrades Minerva Neurosciences (NERV) to "Buy"
www.americanbankingnews.com - April 12 at 3:27 PM
BRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive DisorderBRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder
www.reuters.com - April 9 at 5:21 PM
Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive DisorderMinerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
finance.yahoo.com - April 9 at 5:21 PM
Minerva Neurosciences (NERV) Upgraded at Zacks Investment ResearchMinerva Neurosciences (NERV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 9 at 2:26 PM
Minerva Neurosciences (NERV) Upgraded at BidaskClubMinerva Neurosciences (NERV) Upgraded at BidaskClub
www.americanbankingnews.com - April 6 at 10:46 AM
Minerva Neurosciences (NERV) Lifted to "Sell" at ValuEngineMinerva Neurosciences (NERV) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - April 5 at 1:55 PM
Minerva Neurosciences Inc (NERV) Expected to Announce Earnings of -$0.30 Per ShareMinerva Neurosciences Inc (NERV) Expected to Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - March 28 at 3:08 AM
Will Minerva Neurosciences (NERV) Continue to Surge Higher? March 23, 2018Will Minerva Neurosciences (NERV) Continue to Surge Higher? March 23, 2018
www.zacks.com - March 24 at 5:15 PM
Will Minerva Neurosciences (NERV) Continue to Surge Higher?Will Minerva Neurosciences (NERV) Continue to Surge Higher?
finance.yahoo.com - March 23 at 5:42 PM
Minerva Neurosciences (NERV) Rating Increased to Buy at Zacks Investment ResearchMinerva Neurosciences (NERV) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 17 at 12:04 PM
Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday ... - GlobeNewswire (press release)Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday ... - GlobeNewswire (press release)
globenewswire.com - March 16 at 8:21 AM
Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22
finance.yahoo.com - March 15 at 6:11 PM
Brokers Offer Predictions for Minerva Neurosciences Incs FY2018 Earnings (NERV)Brokers Offer Predictions for Minerva Neurosciences Inc's FY2018 Earnings (NERV)
www.americanbankingnews.com - March 15 at 9:04 AM
Jefferies Group Comments on Minerva Neurosciences Incs Q1 2018 Earnings (NERV)Jefferies Group Comments on Minerva Neurosciences Inc's Q1 2018 Earnings (NERV)
www.americanbankingnews.com - March 14 at 7:21 AM
Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates - GlobeNewswire (press release)Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates - GlobeNewswire (press release)
www.globenewswire.com - March 12 at 6:38 PM
Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and ... - NasdaqMinerva Neurosciences Reports Fiscal 2017 Fourth Quarter and ... - Nasdaq
www.nasdaq.com - March 12 at 6:38 PM
Minerva Neurosciences posts 4Q profitMinerva Neurosciences posts 4Q profit
finance.yahoo.com - March 12 at 9:15 AM
Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business UpdatesMinerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates
finance.yahoo.com - March 12 at 9:15 AM
Minerva Neurosciences Inc (NERV) Expected to Announce Earnings of -$0.43 Per ShareMinerva Neurosciences Inc (NERV) Expected to Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - March 10 at 9:20 PM
Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates ... - GlobeNewswire (press release)Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates ... - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:15 AM
Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018
finance.yahoo.com - March 5 at 5:49 PM
Ascend Capital LLC Has $4.96 Million Stake in Minerva Neurosciences Inc (NERV)Ascend Capital LLC Has $4.96 Million Stake in Minerva Neurosciences Inc (NERV)
www.americanbankingnews.com - March 1 at 4:42 AM
Minerva Neurosciences, Inc (NERV) Given Average Recommendation of "Hold" by BrokeragesMinerva Neurosciences, Inc (NERV) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 23 at 1:44 AM
Zacks: Analysts Anticipate Minerva Neurosciences, Inc (NERV) to Announce -$0.43 Earnings Per ShareZacks: Analysts Anticipate Minerva Neurosciences, Inc (NERV) to Announce -$0.43 Earnings Per Share
www.americanbankingnews.com - February 22 at 5:08 AM
Minerva Neurosciences, Inc (NERV) Short Interest UpdateMinerva Neurosciences, Inc (NERV) Short Interest Update
www.americanbankingnews.com - February 12 at 4:08 AM
TBPH Inks $1Bln Deal, SGMO Hits Yearly High, ANAB Is Back AgainTBPH Inks $1Bln Deal, SGMO Hits Yearly High, ANAB Is Back Again
www.nasdaq.com - February 8 at 8:11 AM
BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive ChairmanBRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman
www.reuters.com - February 5 at 9:40 AM
Minerva Neurosciences, Inc.: Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent DirectorMinerva Neurosciences, Inc.: Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director
www.finanznachrichten.de - February 5 at 9:40 AM
Minerva Neurosciences (NERV) Downgraded to Strong Sell at ValuEngineMinerva Neurosciences (NERV) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - February 4 at 8:40 PM
Head-To-Head Comparison: Minerva Neurosciences (NERV) & Its PeersHead-To-Head Comparison: Minerva Neurosciences (NERV) & Its Peers
www.americanbankingnews.com - February 2 at 5:12 PM
Minerva Neurosciences, Inc (NERV) Given Consensus Rating of "Hold" by BrokeragesMinerva Neurosciences, Inc (NERV) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 29 at 1:28 AM

SEC Filings

Minerva Neurosciences (NASDAQ:NERV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Minerva Neurosciences (NASDAQ:NERV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Minerva Neurosciences (NASDAQ NERV) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.